Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab for Advanced Cervical Cancer
Recruiting1 awardPhase 2
Missoula, Montana
This trial is testing nivolumab to treat patients with cervical cancer that has returned or spread. Nivolumab is a monoclonal antibody that may help to block tumor growth.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service